| ²é¿´: 1076 | »Ø¸´: 17 | ||||
| ¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û17´Î£¬×÷ÕßÁõÐ¡ÒæÔö¼Ó½ð±Ò 12.8 ¸ö | ||||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||||
[×ÊÔ´]
Proteomics in Practice[2008]
|
||||
Ò»±¾ºÜÏêϸµÄ½éÉܵ°°×ÖÊ×éѧ·½·¨¼°·¢Õ¹µÄÊé~~![]() ![]() ![]() |
» ±¾Ìû¸½¼þ×ÊÔ´Áбí
-
»¶Ó¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com - ¸½¼þ 1 : ProteomicsinPractice[2008].pdf
2012-09-29 17:36:31, 6.62 M
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
¹úÍâרҵµç×ÓÊé1 | Biotech×ÊÁÏ |
» ²ÂÄãϲ»¶
Wnt-C59£ºPORCN°ÐÏò»¯Ñ§Ì½Õ룬WntÐźÅͨ·×è¶Ï»úÖÆÓë¿ÆÑÐÓ¦ÓÃÈ«½âÎö
ÒѾÓÐ0È˻ظ´
Fexaramine£º³¦µÀÏÞÖÆÐÔFXR»¯Ñ§Ì½Õ룬½á¹¹ÌØÕ÷ÓëÐźÅͨ·Ñо¿È«½âÎö
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ178È˻ظ´
NVS-STG2£º°ÐÏòSTING¿çĤÓòµÄ·Ö×Ó½ºÀ༤¶¯¼Á£¬½á¹¹ÌØÕ÷Óë¹Ñ¾Û»¯»úÖÆÑо¿È«½âÎö
ÒѾÓÐ0È˻ظ´
DOTA-GPC3ëÄ£¨CAS 3066439-94-6£©£ºË«¹¦ÄÜ·Ö×Ó̽ÕëǰÌåµÄ½á¹¹ÌØÕ÷Óë±ê¼ÇÓ¦ÓýâÎö
ÒѾÓÐ0È˻ظ´
¿ÆÑÐÓà TLR7/8 Ë«¼¤¶¯¼ÁÔõôѡ£¿ÏÖ»õÓëÖÊ¿ØÒªµã
ÒѾÓÐ0È˻ظ´
SEL120-34A HCl£ºCDK8/CDK19¸ßÑ¡ÔñÐÔ¼¤Ã¸ÒÖÖÆ¼Á
ÒѾÓÐ0È˻ظ´
ÇâÑõ»¯¼Ø»î»¯²Ù×÷
ÒѾÓÐ18È˻ظ´
É¢½ð
ÒѾÓÐ68È˻ظ´
ÉúÎïÖʳ¬¼¶µçÈÝÆ÷
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÓйØÍÁÈÀ΢ÉúÎÖ÷ÒªÊÇÉú·À¾ú£©µÄÏà¹ØSCIÓÐÄÄЩ¿ÉͶ°¡£¿
ÒѾÓÐ4È˻ظ´
Method_Validation_in_Pharmaceutical_Analysis___A_Guide_to_Best_Practice
ÒѾÓÐ73È˻ظ´
WileyÉúÃü¿ÆÑ§ÀàÊé¼®»ã×Ü
ÒѾÓÐ67È˻ظ´
7Â¥2012-10-03 12:27:08
12Â¥2012-10-07 03:21:23
¼òµ¥»Ø¸´
zhp2Â¥
2012-09-30 01:17
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
jinhx873Â¥
2012-10-01 08:54
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
Chengxm4Â¥
2012-10-01 12:06
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
diandong5Â¥
2012-10-01 19:41
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
yinxiangxv6Â¥
2012-10-02 20:43
»Ø¸´
ÈýÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
stratchclyde8Â¥
2012-10-04 23:08
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
±±äéÓã13189Â¥
2012-10-05 11:11
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
lindoudou10Â¥
2012-10-05 12:11
»Ø¸´
ÈýÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
wtiger11Â¥
2012-10-05 13:24
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
bradyluo14Â¥
2012-10-25 14:08
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡










»Ø¸´´ËÂ¥
20